Gilead Sciences Newsroom

Today's Analyst Rating | Deutsche Bank Upgrades Boston Scientific to Buy, Morgan Stanley Upgrades Gilead Sciences to Buy

Jan 10, Wall Street analysts have updated their stock ratings today including $Boston Scientific(BSX.US)$ and $Gilead Sciences(GILD.US)$.

Futu News21:00 · Ratings

Gilead Sciences Analyst Ratings

Benzinga19:29 · Ratings

Express News | Gilead Sciences Inc. : Morgan Stanley Raises to Overweight From Equal-Weight

Breakings19:28

Morgan Stanley Upgrades Gilead Sciences(GILD.US) to Buy Rating, Raises Target Price to $113

Futu News18:35 · Ratings

Trump Says World Is Free-Riding on U.S. Health Spending. He Has a Point. -- WSJ

WSJ18:30

Gilead Sciences: Buy Rating Backed by Promising Pipeline and Attractive Valuation

TipRanks18:16 · Ratings

Express News | Morgan Stanley raised Gilead Sciences' rating to Overweight, with a Target Price of $113.

Breakings13:16

Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know

Yahoo Finance07:00

Pharma Companies Welcome New Year With 583 Drug Price Hikes so Far

Seeking Alpha04:36

Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference

Benzinga03:12

Drugs Not Selected for Medicare Price Negotiation Nearly Doubled - Report

Seeking Alpha00:35

Novo, Eli Lilly to Dominate Global Pharma Sales in 2025: Report

Seeking AlphaJan 9 21:56

Gilead Sciences Hits 6-week Low

Trading EconomicsJan 9 04:54

Galapagos Unveils 2025 Split To Accelerate Innovation, Sharpen Strategic Focus

BenzingaJan 9 03:07

Unusual Options Activity: IVZ, HIMS and Others Attract Market Bets, IVZ V/OI Ratio Reaches 198.8

EST Jan 8th Morning Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.

Futu NewsJan 9 00:30

Galapagos Plans to Split Into Two Entities, Revise Agreement With Gilead Sciences, Reduce Workforce by 40%

MT NewswiresJan 8 20:16

Compugen Announced That The First Patient Was Dosed In A Phase 1 Clinical Trial With Com503, A Potential First-in-class Antibody Against Il-18 Binding Protein Licensed By Compugen To Gilead

BenzingaJan 8 20:04

Express News | Corrected-Buzz-Pharma Group Galapagos Jumps 11% on Planned Split

BreakingsJan 8 17:55

Looking Into Gilead Sciences's Recent Short Interest

BenzingaJan 8 02:00

Gilead Sciences, Inc. (NASDAQ:GILD) Is a Favorite Amongst Institutional Investors Who Own 86%

Simply Wall StJan 7 21:48